BMPR2 and pulmonary arterial hypertension: To investigate whether MnTBAP treatment increases BMPR2 protein levels in the context of PAH, primary human PAECs were treated with MnTBAP and the lysosomal inhibitor bafilomycin A1 (BafA1) as a positive control.